recent
year
studi
three
broadli
activ
viral
inhibitor
produc
spontan
bodi
cell
cultur
tent
name
contactblock
viral
inhibitor
cvi
b
uti
c
uti
inhibitor
origin
univers
texa
natur
produc
inhibitor
may
serv
host
defens
number
viru
group
understand
inhibitor
structur
mechan
antivir
action
may
lead
new
insight
mechan
viruscel
interact
ultim
medic
use
number
viral
inhibitor
occur
bodi
inhibitor
includ
antibodi
interferon
induc
consequ
viral
infect
inhibitor
occur
uninfect
host
rang
narrow
broad
antivir
activ
inhibit
virus
divers
mechan
three
spontan
occur
inhibitor
present
review
appear
structur
function
distinct
previous
report
inhibitor
see
understand
differ
among
three
antivir
substanc
grown
investig
progress
origin
common
attribut
three
inhibitor
e
g
widespectrum
antivir
action
blockag
attach
mani
virus
target
cell
resist
denatur
extrem
ph
caus
us
mistakenli
believ
singl
molecular
moieti
involv
antivir
activ
summar
detail
investig
allow
us
delin
least
three
molecularli
distinct
inhibitor
describ
base
current
understand
introduc
revis
nomenclatur
help
clarifi
discuss
inhibitor
three
inhibitor
present
share
one
major
characterist
broad
antivir
activ
tabl
distinguish
featur
three
inhibitor
molecular
size
essenti
chemic
composit
thermal
chemic
stabil
physiolog
site
occurr
summari
principl
characterist
three
antivir
substanc
present
tabl
author
correspond
address
academ
press
limit
tabl
antivir
spectrum
three
naturallyoccur
inhibitor
plaqu
reduct
titer
except
hemagglutin
yield
reduct
influenza
revers
transcriptas
assay
cell
assay
vari
viru
test
test
refer
unpublish
observ
refer
unpublish
observ
refer
unpublish
observ
cvi
first
detect
unexpectedli
character
interferon
prepar
tissu
cultur
interferon
prepar
studi
contain
second
inhibitor
cvi
properti
clearli
differenti
interferon
previous
report
inhibitor
distinguish
properti
cvi
includ
inhibit
attach
mani
virus
cell
appar
molecular
size
kda
essenti
peptid
carbohydr
structur
high
stabil
physic
chemic
agent
revers
inhibit
product
number
cell
cultur
uti
x
discov
unexpectedli
survey
bodi
fluid
tissu
extract
cvi
found
previous
cell
cultur
mani
bodi
fluid
tissu
extract
contain
broadli
activ
viral
inhibitor
properti
clearli
distinct
cvi
tabl
properti
distinguish
uti
x
cvi
intracellular
addit
broad
extracellular
inhibit
influenza
varicellazost
virus
molecular
size
da
probabl
essenti
carbohydr
structur
extrem
thermal
stabil
presenc
mani
bodi
fluid
tissu
extract
uti
discov
human
sera
found
broad
spectrum
antivir
activ
normal
human
serum
distinct
cvi
uti
x
unpublish
observ
although
uti
share
broad
antivir
spectrum
cvi
uti
distinguish
molecular
size
approxim
kda
labil
convers
heat
stabl
low
molecular
weight
inhibitor
proteolysi
inactiv
mild
oxid
period
suggest
essenti
carbohydr
structur
preliminari
experi
antivir
activ
partial
revers
wash
cell
interestingli
human
serum
also
contain
low
level
small
molecular
weight
approxim
kda
inhibitor
may
relat
kda
proteas
digest
product
kda
inhibitor
begun
character
purifi
three
inhibitor
appear
novel
broadli
antivir
repres
innat
natur
host
defens
whose
mechan
activ
may
suggest
new
approach
develop
antivir
compound
present
specif
find
inhibitor
antivir
activ
cell
cultur
contact
block
viral
inhibitor
cvi
origin
identifi
broadli
activ
spontan
produc
viral
inhibitor
supernat
varieti
cell
grown
cultur
inhibitor
act
primarili
block
attach
viru
target
cell
name
contactblock
viral
inhibitor
cvi
cvi
produc
variou
primari
secondari
cell
line
human
murin
origin
continu
human
mous
sheep
rabbit
cell
line
j
youngner
person
commun
level
antivir
activ
produc
vari
low
high
produc
cell
line
primari
mous
embryo
fibroblast
mef
sever
passag
shown
consist
produc
signific
cvi
activ
unitsml
use
partial
purif
character
cvi
product
cvi
independ
cell
densiti
subcultur
protocol
except
note
mef
produc
cvi
sever
passag
addit
produc
constitut
rapidli
signific
level
observ
cultur
supernat
cell
monolay
begin
within
h
wash
fresh
media
spontan
continu
product
also
suggest
sinc
inhibit
macromolecular
synthesi
treat
cell
actinomycin
cyclohexamid
block
appear
inhibitor
shown
tabl
cvi
possess
broad
univers
antivir
activ
signific
antivir
activ
observ
repres
dna
envelop
nonenvelop
rna
virus
herp
poxvirus
picorna
alpha
rhabdovirus
lack
signific
antivir
activ
ndv
distinguish
cvi
nonspecif
inhibitor
found
tissu
physiolog
fluid
uti
uti
discuss
later
review
critic
differ
cvi
anoth
broadli
antivir
substanc
interferon
absenc
speci
specif
cvi
although
rel
antivir
titer
cvi
given
sourc
differ
assay
variou
cell
type
cvi
shown
activ
heterolog
cell
line
test
interestingli
obviou
correl
rel
antivir
titer
observ
cell
type
heterolog
cvi
abil
produc
cvi
cultur
mechan
action
cvi
appear
rapidli
revers
nonprogress
extracellular
inhibit
viral
attach
cell
membran
regard
antivir
activ
remov
wash
andor
dilut
observ
cvi
introduc
viral
infect
cell
singl
cycl
viru
growth
experi
addit
antivir
activ
reduc
incub
viru
properti
consist
substanc
display
low
affin
revers
bind
viral
particl
cell
interf
subsequ
attach
cell
surfac
chemic
physic
properti
cvi
summar
tabl
antivir
activ
distinct
broad
spectrum
viral
inhibitor
virtu
larg
molecular
size
gel
filtrat
chromatographi
ultrafiltr
experi
suggest
antivir
compon
extrem
larg
appar
molecular
weight
da
sediment
discontinu
sucros
gradient
yield
antivir
activ
sediment
rate
equival
kda
fig
sucros
densiti
gradient
sediment
mous
embryo
cvi
equal
volum
mous
embryo
fibroblast
cvi
antivir
unit
sucros
mix
appli
top
discontinu
sucros
gradient
centrifug
x
g
min
gradient
fraction
ml
collect
dialyz
give
final
sucros
concentr
assay
antivir
activ
determin
vaccinia
viru
mous
cell
surprisingli
larg
size
unpreced
tammhorsfal
glycoprotein
report
approxim
kda
although
urinari
antivir
molecul
less
heat
stabl
cvi
sediment
cvi
exhibit
biolog
properti
unsedi
materi
activ
vaccinia
polio
hsv
virus
two
alphavirus
vesicular
stomat
viru
inact
ndv
unpublish
observ
possibl
antivir
activ
origin
shed
membran
fragment
exclud
sinc
mef
membran
prepar
freez
thaw
discontinu
sucros
gradient
fail
show
antivir
activ
activ
effect
extract
lipid
solvent
physicalchem
properti
cvi
quit
distinct
tabl
cvi
possess
thermal
stabil
intermedi
uti
stabl
h
unstabl
antivir
activ
unaffect
treatment
rnase
dnase
ether
butanol
extract
sensit
proteolyt
enzym
mild
oxid
period
howev
cvi
unalt
molecular
size
activ
sulfhydryl
reagent
dithiothreitol
protein
solubil
agent
urea
properti
suggest
carbohydr
polypeptid
compon
requir
activ
nativ
cvi
howev
structur
antivir
surpris
thermal
denatur
stabil
remain
unknown
consid
extracellular
matrix
compon
origin
cvi
howev
studi
relat
compound
like
heparin
carageenan
show
narrow
antivir
spectrum
unpublish
find
therebi
differenti
cvi
inhibitor
describ
low
molecular
weight
inhibitor
physiolog
fluid
tissu
extract
uti
second
type
broadli
activ
viru
inhibitor
found
varieti
bodi
secret
tissu
extract
other
detect
inhibitor
properti
match
given
tabl
bovin
human
milk
mous
rabbit
human
gastrointestin
content
extract
mous
rabbit
human
tissu
unpublish
result
similar
activ
uncharacter
present
found
human
nasal
salivari
secret
liver
extract
provision
refer
materi
uti
essenti
characterist
differenti
uti
tissu
culturederiv
inhibitor
cvi
tabl
uti
smaller
molecular
size
extrem
heat
stabil
lack
essenti
peptid
structur
differ
antivir
spectrum
e
g
activ
ndv
critic
featur
differenti
materi
major
inhibitor
found
human
serum
describ
later
small
molecular
size
extrem
heat
stabil
lack
essenti
peptid
structur
size
exclus
chromatographi
softgel
high
perform
liquid
chromatographi
h
plc
support
consist
yield
molecular
size
rang
da
unpublish
result
uti
materi
contain
essenti
peptid
structur
judg
resist
digest
trypsin
chymotrypsin
nonspecif
proteolyt
enzym
proteinas
k
extract
inactiv
organ
solvent
show
extend
stabil
heat
ph
denatur
critic
physicalchem
characterist
summar
tabl
preliminari
work
low
molecular
weight
viru
inhibitor
bodi
fluid
done
materi
bovin
milk
henc
particularli
care
delin
materi
virusinhibitori
substanc
report
milk
presenc
antivir
lipid
milk
well
document
materi
differenti
low
molecular
weight
inhibitor
tissu
bodi
fluid
least
three
area
envelop
virus
affect
antivir
milk
lipid
wherea
uti
activ
envelop
nonenvelop
virus
b
mechan
action
milk
lipid
antivir
appear
disrupt
lipid
contain
surfac
membran
envelop
virus
lead
loss
integr
viru
particl
consequ
loss
infect
uti
contrast
appear
function
virus
prevent
disrupt
effect
contact
viru
target
cell
inactiv
viru
cellfre
system
c
uti
found
aqueou
fraction
milk
lipid
rich
cream
layer
addit
milk
whey
gastrointestin
inhibitor
uti
extract
organ
solvent
antivir
activ
degrad
remain
aqueou
phase
second
viru
inhibitor
present
bovin
milk
whey
also
distinguish
antivir
substanc
review
inhibitor
activ
test
rhabdovirus
orthomyxovirus
rhinovirus
reovirus
vitro
appear
directli
inactiv
viru
activ
locat
aqueou
fraction
milk
ether
extract
significantli
howev
inhibitor
moder
heat
stabl
min
destroy
treat
min
sharp
contrast
remark
heat
stabil
uti
stabl
least
h
least
min
assay
antivir
activ
uti
present
proprietari
pharmaceut
formul
neuramid
difa
pharmaceut
number
bovin
milkderiv
proprietari
infant
formula
signific
antivir
activ
detect
aqueou
fraction
e
g
antindv
unitsml
infant
formula
undergon
high
heat
treatment
manufactur
addit
uti
clearli
depend
intact
protein
structur
activ
tabl
contrast
materi
describ
previous
final
bovin
milk
whey
inhibitor
uti
pass
freeli
small
pore
minim
retent
dialysi
tube
taken
togeth
characterist
serv
distinguish
uti
nonspecif
antivir
activ
report
milk
number
biolog
test
carri
character
uti
lx
assay
inhibitorcontain
prepar
human
bovin
milk
cell
line
primat
rodent
avian
origin
unlik
interferon
antivir
effect
speci
specif
evid
cell
line
test
howev
degre
inhibit
vari
cell
type
use
assay
even
viru
assay
activ
produc
durabl
antivir
state
target
cell
sinc
cell
revert
suscept
inhibitor
prepar
thoroughli
wash
preliminari
studi
crude
antivir
prepar
bovin
milk
indic
major
antivir
effect
inhibitor
prevent
attach
target
cell
vaccinia
polio
hsv
nd
virus
howev
differ
mode
action
detect
studi
vsv
varicella
zoster
vz
influenza
hiv
vsv
inhibit
earli
postpenetr
step
viral
infect
judg
greater
inhibit
vsv
vs
time
viru
escap
inhibit
time
addit
inhibitor
viru
infect
monolay
unpublish
observ
vz
influenzaa
perhap
hiv
hand
appear
inhibit
late
replic
cycl
unpublish
result
final
determin
whether
antivir
activ
viral
attach
replic
repres
differ
action
singl
inhibitor
whether
repres
differ
inhibitori
speci
await
studi
use
purifi
materi
although
structur
uti
determin
number
line
evid
consist
activ
moieti
contain
carbohydr
oligosaccharid
structur
neg
evid
summar
tabl
indic
peptid
nucleic
acid
lipid
structur
essenti
antivir
activ
inhibitor
chromatograph
evid
obtain
purif
inhibitori
activ
also
consist
carbohydr
structur
e
inhibitori
activ
slight
affin
heparin
boron
affin
hplc
column
retain
varieti
lectin
affin
column
unpublish
observ
profil
partial
purifi
inhibitor
milk
whey
hplc
column
optim
separ
carbohydr
shown
fig
materi
elut
column
repres
purif
antivir
substanc
base
recoveri
activ
optic
densiti
measur
investig
structur
activ
molecul
current
way
broadli
activ
viral
inhibitor
human
serum
uti
also
detect
third
broadli
activ
viral
inhibitor
found
human
serum
provision
term
uti
uti
occur
normal
serum
signific
titer
uml
activ
wide
rang
virus
cell
differ
speci
tabl
uti
differ
cvi
uti
size
themost
chemic
natur
tabl
unpublish
observ
uti
appear
nativ
molecular
size
rang
kda
base
hplc
size
exclus
chromatographi
show
moder
heat
stabil
denatur
treatment
greater
min
unpublish
observ
uti
possess
protein
compon
essenti
antivir
activ
unlik
uti
x
protein
free
cvi
essenti
protein
uti
show
antivir
activ
envelop
nonenvelop
rna
envelop
dna
virus
tabl
inhibitori
activ
vari
viru
use
rang
uml
uniformli
higher
envelop
rna
virus
human
serum
also
contain
smaller
broadli
activ
viral
inhibitor
pass
dialysi
tube
kda
retent
constitut
total
viru
inhibit
activ
approxim
nonspecif
antivir
activ
retain
condit
repres
proteinbound
antivir
activ
kda
identifi
uti
light
presenc
minor
small
molecular
weight
serum
activ
routin
remov
compon
analysi
uti
thu
experi
summar
character
uti
serum
first
exhaust
dialys
remov
small
molecular
weight
antivir
compon
nativ
uti
appear
possess
protein
carbohydr
structur
prepar
mild
oxid
sodium
metaperiod
destroy
uti
activ
suggest
carbohydr
structur
essenti
antivir
activ
proteolyt
digest
consist
increas
inhibitor
activ
threefold
howev
tabl
antivir
activ
proteasedigest
uti
associ
newli
gener
kda
compon
data
rais
sever
possibl
structur
nativ
uti
nativ
uti
could
repres
polymer
multimer
structur
anoth
possibl
small
kda
antivir
molecul
specif
nonspecif
bound
carrier
protein
serum
tabl
also
show
proteas
digest
activ
stabl
least
min
previous
report
viru
inhibitori
activ
serum
exist
sever
molecular
compon
convers
larg
size
inhibitor
smaller
inhibitor
properti
similar
observ
uti
suggest
evid
uti
may
relat
howev
preliminari
attempt
gener
small
molecular
weight
inhibitor
disrupt
nativ
structur
uti
sulfhydryl
chaotrop
agent
unsuccess
tabl
unpublish
observ
nevertheless
experi
elimin
possibl
natur
occur
small
molecular
weight
inhibitor
sera
see
relat
proteasereleas
form
uti
may
molecul
exist
equilibrium
mechan
action
uti
appear
complex
inhibitor
bind
tightli
viru
particl
sinc
infect
viru
recov
simpli
dilut
virusinhibitor
mixtur
one
mode
action
nativ
uti
prevent
viral
attach
cell
judg
measur
inhibit
viral
infect
absorpt
viru
cell
virus
e
g
hsv
appear
inhibit
postadsorpt
step
howev
result
preliminari
experi
indic
pretreat
cell
nativ
uti
prepar
induc
durabl
antivir
state
bunyamwera
viru
account
signific
portion
antivir
activ
gener
result
remain
test
current
unknown
whether
antivir
activ
repres
surfac
intracellular
phenomenon
whether
one
inhibitor
remain
serum
prepar
precis
evalu
inform
previous
describ
serum
inhibitor
believ
inhibitor
differenti
uti
base
major
differ
properti
antivir
spectrum
heat
stabil
chemic
composit
mechan
antivir
activ
report
describ
inhibitor
either
lipid
base
review
present
properti
three
recent
describ
broadli
activ
innat
viral
inhibitor
properti
appear
distinguish
previous
describ
viral
inhibitor
occur
bodi
one
inhibitor
cvi
produc
spontan
number
cell
cultur
kda
contain
essenti
peptid
probabl
carbohydr
structur
concentr
cvi
normal
present
produc
cultur
inhibit
suscept
virus
low
multipl
infect
use
infect
cell
cultur
second
inhibitor
uti
found
sever
bodi
secret
tissu
extract
less
kda
appear
contain
essenti
carbohydr
structur
third
antivir
inhibitor
uti
found
human
serum
approxim
kda
probabl
compos
essenti
carbohydr
protein
essenti
inhibitori
activ
proteolysi
uti
appear
convert
inhibitor
form
may
resembl
uti
mechan
antivir
action
three
inhibitor
virus
appear
inhibit
viral
attach
step
uti
may
also
inhibit
stage
replic
virus
like
herpesvirus
influenza
viru
major
contact
viral
pathogen
lead
clinic
infect
resist
suggest
possibl
natur
defens
role
inhibitor
like
uti
consist
presenc
import
bodi
site
prior
infect
rel
strong
antivir
effect
evid
natur
defens
role
would
requir
transfer
delet
studi
abil
uti
inhibit
appear
hiv
revers
transcriptas
cell
cultur
deserv
comment
look
question
use
three
differ
experiment
protocol
modest
inhibit
observ
two
three
experi
addit
studi
purifi
potent
prepar
clearli
indic
final
assess
made
broadli
activ
viral
inhibitor
also
found
unconcentr
urin
although
origin
thought
inhibitor
ident
small
inhibitor
tissu
fluid
detail
studi
indic
inhibitor
cvi
uti
uti
involv
instead
inhibit
correl
strongli
concentr
ammonium
ion
urin
ammonium
ion
lysosomotrop
amin
report
inhibit
uncoat
mani
virus
rais
ph
lysosom
thu
inactiv
mani
lysosom
enzym
ammonium
ion
inhibitor
clearli
distinguish
three
inhibitor
describ
herein
base
size
antivir
spectrum
mechan
viral
inhibit
studi
three
nonspecif
viru
inhibitor
describ
herein
rais
mani
question
may
address
futur
research
fulli
understand
function
mechan
action
antivir
activ
necessari
purifi
structur
analyz
possibl
relationship
larg
uti
small
uti
inhibitor
circul
serum
need
unravel
cell
develop
resist
viral
infect
incub
uti
q
requir
metabol
function
alter
becom
protect
intracellular
cell
surfac
event
broad
rang
virus
affect
substanc
impli
common
viral
attach
pathway
affect
inhibitor
molecular
moieti
fact
affect
attach
late
replic
event
differ
virus
physiolog
question
includ
site
product
secret
elimin
inhibitor
properti
broadli
activ
inhibitor
bodi
fluid
tissu
e
g
respiratori
secret
tear
saliva
liver
extract
level
inhibitor
chang
infect
question
possibl
medic
use
includ
level
endogen
inhibitor
vivo
elev
suffici
exogen
inhibitor
protect
viral
infect
side
effect
final
concern
defens
role
inhibitor
affect
pathogen
virus
present
evid
three
distinct
broadli
activ
viral
inhibitor
occur
spontan
bodi
fluid
tissu
extract
cell
cultur
may
account
bodi
resist
virus
open
number
avenu
futur
research
